Drugs / CSB-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06452316 | May 2024 → Dec 2027 expected | limbal stem cell deficiency | Claris Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06257355 | Feb 2024 → Jun 2027 expected | corneal disorder | Claris Biotherapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04909450 | Aug 2021 → May 2024 | neurotrophic keratopathy | Claris Biotherapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | Kringle Pharma, Inc. | Results 提携先のクラリス・バイオセラピューティクス社によるシリーズB資金調達、今後の開発計画、及び経営体制強化のお知らせ kringle-pharma.com ↗ |
| 2026-07-28 | Claris Biotherapeutics, Inc. | Results Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments clarisbio.com ↗
Positive proof-of-concept clinical data show substantial improvements in visual acuity in limbal stem cell deficiency (LSCD) patients treated with CSB-001 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | Kringle Pharma, Inc. | 提携先のクラリス・バイオセラピューティクス社によるシリーズB資金調達、今後の開発計画、及び経営体制強化のお知らせ kringle-pharma.com ↗ |
| 2026-07-28 | Claris Biotherapeutics, Inc. | Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments clarisbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06452316 ↗ |
| Known as | dHGF | “CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)” NCT04909450 ↗1“CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)” NCT06452316 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)” NCT04909450 ↗ |
| Route | Topical | “One drop CSB-001 four times daily for 8 weeks in the study eye” NCT04909450 ↗ |